Trials / Completed
CompletedNCT00830063
Tanezumab In Osteoarthritis Of The Knee (2)
A PHASE 3 RANDOMIZED, DOUBLE BLIND PLACEBO AND NAPROXEN CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 832 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | tanezumab 10 mg | tanezumab 10 mg one dose at weeks 0 and 8 |
| BIOLOGICAL | tanezumab 5 mg | tanezumab 5 mg one dose at weeks 0 and 8 |
| DRUG | naproxen | naproxen 1000 mg daily for 16 weeks |
| OTHER | placebo | placebo to match tanezumab and naproxen dosing |
Timeline
- Start date
- 2009-05-05
- Primary completion
- 2010-05-17
- Completion
- 2010-08-31
- First posted
- 2009-01-27
- Last updated
- 2021-05-13
- Results posted
- 2021-05-13
Locations
94 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00830063. Inclusion in this directory is not an endorsement.